Development of PARP inhibitors in gynaecological malignancies

PARP inhibitors demonstrate synthetic lethality in tumours with BRCA1/2 mutations and other homologous recombination repair deficiencies by interfering with DNA repair and causing direct toxicity to DNA through PARP trapping. PARP inhibitors have been shown to be beneficial in the treatment of BRCA1/2 mutated ovarian cancers, which has led to a shift in the treatment paradigm of this disease. Further studies to establish the role of PARP inhibitors during earlier stages of treatment are ongoing.

Source: Current Problems in Cancer - March 15, 2017 Category: Cancer & Oncology Authors: Yvonne LE Ang, David SP Tan Source Type: research